Has Michael Boxer received payments from drug or device companies?

Yes. Drug and device makers reported $30,034 in general payments to Michael Boxer across 247 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Boxer did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Boxer come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Boxer

Hematology & Oncology · Tucson, AZNPI 1275502544

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,635 of the $30,034 with a category attached, or 62.0%. 42 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 30.8% of the total. Reporting peaked in 2019 at $22,011 and has fallen 99.9% since, to $15 in 2022.

$30,034in general payments, 2019–2025

Across 247 payments — averaging $121.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$9K
AbbVie$6K
Sanofi$3K
Adaptive Biotechnologies Corporation$2K
F. Hoffmann-la Roche AG$2K
Karyopharm Therapeutics Inc.$2K
plus $6K from 36 others

$96,913in research payments, 2019–2025

Across 31 payments — averaging $3126.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bioverativ Therapeutics Inc.$37K
Genentech, Inc.$26K
Rigel Pharmaceuticals, Inc.$23K
Acerta Pharma LLC$6K
F. Hoffmann-la Roche AG$5K

What the payments were for

Consulting fees$5,87520%
Speaking & faculty fees$18,63562%
Travel & lodging$1,4885%
Food & beverage$3,80913%
Education$2281%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	12	$9,252
AbbVie	5	$5,849
Sanofi	9	$3,094
Adaptive Biotechnologies Corporation	2	$2,095
F. Hoffmann-la Roche AG	4	$2,052
Karyopharm Therapeutics Inc.	3	$1,585
Beigene USA, Inc.	1	$1,350
Beigene, Ltd.	2	$975
Pharmacosmos Therapeutics Inc.	2	$667
Amgen	27	$327
Genentech USA, Inc.	17	$278
E.r. Squibb & Sons, L.L.C.	20	$262
Pfizer	29	$224
Johnson & Johnson	10	$218
Bayer	17	$203
AstraZeneca(2 entities)	12	$190
Merck	17	$176
Aurobindo Pharma USA, Inc.	4	$162
Agios Pharmaceuticals, Inc.	1	$140
Novartis	9	$129
Astellas Pharma US Inc	3	$124
Pharmacyclics LLC, An Abbvie Company	7	$122
Lilly USA, LLC	4	$53
Sun Pharmaceutical Industries Inc.	2	$47
Boehringer Ingelheim	3	$42
Bristol Myers Squibb	2	$41
Puma Biotechnology, Inc.	2	$38
Gilead	3	$37
Incyte Corporation	2	$37
Exelixis Inc.	2	$34
Dova Pharmaceuticals	2	$30
Cardinal Health 414 LLC	1	$29
Seagen Inc.	2	$26
Shire North American Group Inc	1	$24
Sanofi-aventis U.S. LLC	1	$21
Regeneron Healthcare Solutions, Inc.	1	$18
Advanced Accelerator Applications	1	$18
AMAG Pharmaceuticals, Inc.	1	$16
Blueprint Medicines Corporation	1	$15
Ipsen Biopharmaceuticals, Inc	1	$13
Secura Bio, Inc.	1	$13
Clovis Oncology, Inc.	1	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NINLARO$8,964
Venclexta$5,749
CEREZYME$2,877
CERDELGA$2,877
BRUKINSA$2,325
GAZYVA$2,052
clonoSEQ$2,000
XPOVIO$1,550
Monoferric$656
TIBSOVO$140
Beleodaq$134
Folotyn$134

How this compares

$30,034 in reported general payments places this provider in the 80th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona →

Other hematology & oncology in Tucson

Christopher ChenTucson$370K
Rachna ShroffTucson$250K
Alison StopeckTucson$115K
Jaspreet ChahalTucson$104K
Basel ShouaTucson$98K
Akshay AmaraneniTucson$93K
Ahmed AbdelazizTucson$35K
Catherine AzarTucson$29K
Ricklie JulianTucson$27K
Sujith KalmadiChandler$1.4M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →